Bracco company Blue Earth Diagnostics and Siemens Healthineers business PETNET Solutions have announced the commercial availability of the formers’ Posluma (flotufolastat F 18) Injection for PET imaging of prostate cancer in the US.

In May this year, the US Food and Drug Administration approved Posluma, which is now supplied via several of PETNET’s radiopharmacies.

PETNET is the primary manufacturer and commercial distributor for Blue Earth Diagnostics in the US.

Posluma’s commercial production will be underway at the 31 PETNET radiopharmacies across the country by the end of this month, as part of Blue Earth Diagnostics' New Drug Application.

By the end of this summer, additional PETNET sites are anticipated to manufacture this injection.

PETNET Solutions head Barry Scott said: “With our large national network of cyclotron-equipped radiopharmacies, we are well-positioned to provide broad access to Posluma, as well as a wide range of other novel PET biomarkers that facilitate precision medicine for healthcare providers across the country.”

Posluma is an optimised, high-affinity radiohybrid prostate-specific membrane antigen (PSMA)-targeted PET imaging agent.

It is intended for positron emission tomography (PET) of PSMA-positive lesions in prostate cancer men with suspected metastasis.

Posluma is applicable for candidates requiring initial definitive therapy or suspected to have a recurrence based on elevated serum prostate-specific antigen level.

Blue Earth Diagnostics CEO Dr David Gauden said: “Our product introduction plan for Posluma includes practical education programmes for physicians and staff at imaging centres to educate them on the appropriate use of Posluma, including image acquisition and reader training programmes to help ensure the best information is available to inform patient care.”